In the competitive GLP-1 market, non-inferiority data against Novo Nordisk’s market-leading Victoza will go a long way toward strengthening the commercial case for Lilly’s once-weekly GLP-1, dulaglutide, pending at FDA.

The Indianapolis-based pharma highlighted the Phase III results from two of its most promising pipeline candidates at ADA. The company is preparing to have four new diabetes drugs on the market by 2016, including two basal insulins, a GLP-1 agonist and a SGLT-2 inhibitor.

The company expects to present dulaglutide as another option for patients and expand the market instead of trying to switch patients already using GLP-1s, but analysts are interested in how it stacks up against the competition.